|
카테고리
|
Others
|
|
CAT.NO
|
LGP-60-047
|
|
PRODUCT
|
Recombinant Human Galectin-3
|
|
SIZE
|
50ug, 250ug, 1mg
|
|
PRICE
|
KRW 285,000, 555,000, 3,300,000
|
Technical Parameters
| Synonyms |
AGE-R3, CBP35, GAL3, L29, LGALS3, Mac-2 |
| Species |
9 |
| Accession |
P17931 |
| GeneID |
3958 |
| Source |
Escherichia coli. |
| Molecular Weight |
Approximately 26.0 kDa, a single non-glycosylated polypeptide chain containing 249 amino acids. |
| Quantity |
50µg/250µg/1000µg |
| AA Sequence |
ADNFSLHDAL SGSGNPNPQG WPGAWGNQPA GAGGYPGASY PGAYPGQAPP GAYPGQAPPG AYPGAPGAYP GAPAPGVYPG PPSGPGAYPS SGQPSATGAY PATGPYGAPA GPLIVPYNLP LPGGVVPRML ITILGTVKPN ANRIALDFQR GNDVAFHFNP RFNENNRRVI VCNTKLDNNW GREERQSVFP FESGKPFKIQ VLVEPDHFKV AVNDAHLLQY NHRVKKLNEI SKLGISGDID LTSASYTMI |
| Purity |
> 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by its ability to agglutinate human red blood cells is less than 10 μg/ml. |
| Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 µm filtered solution in 1 × PBS, pH 7.4, 3mM DTT. |
| Endotoxin |
Less than 0.1 EU/µg of rHuGalectin-3 as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Usage |
This material is offered by Korea Lugen Sci for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. |
| SDS-PAGE |
 |
| Reference |
1. J Dumic, S Dabelic, M Flogel. 2006. Biochim Biophys Acta, 1760: 616-35.
2. J Raimond, DB Zimonjic, C Mignon, et al. 1997. Mamm Genome, 8: 706-7.
3. DN Cooper. 2002. Biochim Biophys Acta, 1572: 209-31.
4. NC HendersonandT Sethi. 2009. Immunol Rev, 230: 160-71.
5. YP Yan, BT Lang, R Vemuganti, et al. 2009. Brain Res, 1288: 116-24.
6. YH Lin, LY Lin, YW Wu, et al. 2009. Clin Chim Acta, 409: 96-9. |
| Background |
Human Galectin-3 also named AGE-R3, CBP35, GAL3, L29, LGALS3, Mac-2, is belonging to the galectins family and it is encoded by a single gene, LGALS3, located on chromosome 14, locus q21–q22. It is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. Galectin-3 is approximately 30 kDa and, like all galectins, contains a carbohydrate-recognition-binding domain (CRD) of about 130 amino acids that enable the specific binding of β-galactosides. Given Galectin-3’s broad biological functionality, it has been demonstrated to be involved in cancer, inflammation and fibrosis, heart disease, and stroke. Studies have also shown that the expression of galectin-3 is implicated in a variety of processes associated with heart failure, including myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and Ventricular remodeling. Human Galectin-3 shares 79% amino acid sequence identity with rat and mouse Galectin-3, respectively. |
|
|
첨부파일
|
|
|
|
|
|
